Description
BTNL2 Antibody | 22-717 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 246-455 of human BTNL2 (NP_062548.1) .
Research Area: Immunology
Tested Application: WB
Application: WB: 1:500 - 1:2000
Specificiy: N/A
Positive Control 1: HepG2
Positive Control 2: BT-474
Positive Control 3: HL-60
Positive Control 4: 293T
Positive Control 5: Mouse liver
Positive Control 6: N/A
Molecular Weight: Observed: 60kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Concentration: N/A
Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.
Alternate Name: BTL-II, BTN7, HSBLMHC1, SS2, butyrophilin-like protein 2, butyrophilin-like 2 (MHC class II associated) , truncated BTNL2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene encodes a major histocompatibility complex, class II associated, type I transmembrane protein which belongs to the butyrophilin-like B7 family of immunoregulators. It is thought to be involved in immune surveillance, serving as a negative T-cell regulator by decreasing T-cell proliferation and cytokine release. The encoded protein contains an N-terminal signal peptide, two pairs of immunoglobulin-like domains, separated by a heptad peptide sequence, and a C-terminal transmembrane domain. Naturally occurring mutations in this gene are associated with sarcoidosis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease, myositis, type 1 diabetes, systemic lupus erythematosus, acute coronary syndrome, and prostate cancer.